NetworkNewsWire Newsroom

Tuesday, February 2, 2021

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Is ‘One to Watch’

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities
The company has research and development operations in North America and Europe and an operational focus in Germany
XPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual drug formulations, and psychedelic medicine
The company’s lead diagnostic product is an accurate, rapid and highly portable PCR diagnostic test system being evaluated in Europe for the detection of COVID-19
XPhyto’s German subsidiary, Vektor Pharma TF GmbH, is advancing four therapeutic programs targeting neurological indications; the company intends to complete human pilot studies evaluating these products in 2021
The company has two agreements in place focused on psychedelic compounds, a promising new class of API with strong potential for the treatment of mental health conditions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

Commercialization of infectious disease diagnostics
Clinical validation of transdermal and sublingual drug formulations
Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (“CE-IVD”) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

Rotigotine transdermal patch for Parkinson’s disease
CBD oral/sublingual strip for treatment resistant epilepsy
THC oral/sublingual strip for anorexia/nausea
CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://nnw.fm/XPHYF

Brain Scientific Inc. (BRSF) E-Tattoo Will Offer AI Solutions for Neurology

BRSF paving way with next wave of innovation for neurology: e-tattoos
Acceptance of telemedicine, AI here to stay following pandemic
Scientists have learned how to read brain waves using minimally invasive, implantable, four-channel micro EEG to better monitor continuous seizures

The COVID-19 pandemic has accelerated several changes to American culture, many of which appear to be here to stay. According to Harvard experts, some of those changes include movement towards a cashless society, increased remote work, the decline of brick-and-mortar retail, and a new approach to health that includes an acceptance of telemedicine and artificial intelligence (“AI”) (https://nnw.fm/98za1). Brain Scientific (OTCQB: BRSF) is positioned to benefit from that growing acceptance of AI as it focuses on modernizing brain diagnostics.

Early in 2020, Elon Musk announced work on brain interface tech to turn humans into a genius super race. While Musk grabs the spotlight for all things high tech, his brain-computer chip company Neuralink went down as one of many overhyped AI ideas for the year (https://nnw.fm/vUHwD). Musk’s idea might sound like science fiction, allowing an external computer to input data as though the mind is nothing more than a computer processor, but the reverse is a reality.

Elon Musk has dreams of fixing anything wrong with the brain, but before that can be achieved, the problem first needs to be identified and understood. Currently, scientists are working to understand what causes Parkinson’s disease, Alzheimer’s disease, dementia and other neurological issues. The root of the problem must be discovered before the solution is created.

The good news is that BRSF is making inroads in helping identify those problems. The company has unveiled a new initiative to develop a brain E-Tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes would be connected to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. Each patient’s data is secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis. This provides 24/7 uninterrupted seizure monitoring, something that was unavailable previously with the bulky EEGs administered and overseen by specialized techs in hospitals.

The EEG dates back to 1929 and has only seen drastic advances in the last few decades. “COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, co-founder and executive chairman at BRSF (https://nnw.fm/OL19l). “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology.

“The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions,” he continued. “Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life. While we aren’t yet ready as a society to cyborg our way past neurological issues, we are on the cusp of better understanding and diagnosing them. Thanks to cutting-edge technology like BRSF’s e-Tattoo, answers are right around the corner.”

BRSF is committed to modernize brain diagnostics through cutting edge technologies that narrow the widening gap of accessibility to much needed neurological care. In addition to its e-tattoo innovation, the company has received FDA clearance for two transformative EEG products — the NeuroCap(TM) and NeuroEEG(TM) — that have the potential to disrupt the market, provide EEG accessibility and 24/7 EEG coverage where it was once unavailable.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

CannAssist International Corp. (CNSC) Proprietary Tech Is Core of CBD Products with Better Absorption

Absorption vital component of product effectiveness
CNSC’s proprietary CiBiDinol technology is cannabidiol made water compatible
Xceptol products offer CBD in format more in line with body’s natural bioactivity

CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company marketing its exclusive Xceptol consumer brand. The company is the owner of Xceptor Labs, which uses proprietary technology to create Xceptol CBD products. The company complex has better absorption than currently marketed oil-based products — a key advantage when assessing products’ effectiveness.

Drug absorption, or the way a drug is absorbed into the bloodstream, is a vital component in the effectiveness of treatments for a wide variety of diseases and disorders (https://nnw.fm/uFMVx). A product that claims some of the fastest rates on the market is worth paying attention to.

Numerous factors can impact the absorption of a drug into the body, including solubility, drug formulation, administration route, and gastric emptying rate. These are all factors carefully evaluated by CannAssist, which utilizes its proprietary technology — CiBiDinol — in the formulation of its products and offering that technology to third-party providers.

Developed by CannAssist founder Mark Palumbo and available through CNSC’s Xceptor Labs, CiBiDinol technology is cannabidiol made water compatible (https://nnw.fm/de75E). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms. The company’s innovative process combines CBD molecules with penetration-enhancing cyclodextrin, altering the CBD molecule’s surface and rendering it water dispersible. This technology improves absorption through the skin, mucosa and gut; it also enables administration through friendly dosage forms such as capsules, drops, creams and drinks.

CannAssist notes that the technology provides CBD in a format that is more in line with the body’s natural bioactivity. Using this unique approach and exclusive technology as the basis for its entire product line, CannAssist offers an essential component for creating CBD products with more predictable potency.

Xceptor Labs uses CiBiDinol in its CBD products, which have better absorption than currently marketed oil-based products. CannAssist launched its exclusive Xceptol product line in September 2020, which initially included its unscented pain cream formulated with CiBiDinol and ingredients with National Drug Codes registered with the FDA. The company has since added capsules and liquid drops to the product line, with plans for pet drops coming soon.

CannAssist, the owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company. Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation.

For more information, visit the company’s website at www.CannAssistInternational.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://nnw.fm/CNSC

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Monday, February 1, 2021

Gage Cannabis Co. Continues Growth Trajectory, Opens Grand Rapids Location to Eager Community

Gage opens its Grand Rapids, Michigan store — the company’s sixth provisioning center in the state
Store offers more than 40 exclusive strains of flower in addition to variety of pre-rolls, edibles, concentrates, topicals, tinctures, CBD products and more
Gage has single focus: to curate highest-quality cannabis experience possible for its consumers

Gage Cannabis kicked off 2021 with a bang — opening its sixth provisioning center (dispensary) in Michigan and the first in West Michigan (https://nnw.fm/75Lt4). Gage Cannabis is a leading high-quality craft cannabis brand in Michigan.

“As a lifelong resident of Grand Rapids, I’m thrilled to introduce my hometown to Gage,” said Drew McCarthy, store manager and a local media personality. “While the company prides itself on the three Cs — cannabis, culture and community — in my short time with the company I’ve witnessed a fourth C, caring. I’m proud to be part of a company that cares about its employees, cares about its products and cares about the community.”

At this time, the 4,018-square-foot store is only open to medical marijuana cardholders, with orders available for curbside pick-up only. The store offers more than 40 exclusive strains of flower in addition to a variety of pre-rolls, edibles, concentrates, topicals, tinctures, CBD products, accessories and even apparel.

Gage has a single focus: to curate the highest-quality cannabis experience possible for its consumers (https://nnw.fm/yzDU7). The company accomplishes this by growing its own plants in small batches using 100% hydroponic cultivation methods for sustainable and responsible operations. Every plant is handpicked, and then every plant undergoes Gage’s proprietary drying, trimming and curing process, with each step deliberately designed to deliver the best flower possible.

Gage selected Michigan to start its operations based on the state’s fast-growing legal cannabis market and consumer habits. In 2018, Michigan became the 10th state to legalize the recreational use of cannabis. In light of such favorable market dynamics, Gage opened its first medical provisioning center, or dispensary, in 2019. The company now has 13 medical or adult-use locations open or in the works, with an additional 10+ planned to open this year.

About Gage

Gage Cannabis Company is innovating and curating the highest-quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the company’s founding partners have successfully built and grown operations with federal and state licenses including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries).

For more information, visit the company’s website at www.GageUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://nnw.fm/GAGE

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTCQB: ISGIF) Expands Reach with New Global Partnership

InsuraGuest goes live with Guesty, the world’s leading end-to-end short-term rental property management software
Property managers who use Guesty to manage their short-term rentals: rentals which are listed on multiple platforms such as Airbnb, HomeAway, Vrbo, TripAdvisor, Agoda, and Booking.com
Company’s success has hinged not only the caliber of management but even more so on the power of its proprietary software platform.
The InsuraGuest expanded platform integration now connects with 90% of all property management systems used by the biggest names in hospitality.

Technology has now become a key factor in the insurance industry, and it is generating significant changes. The combination of insurance and technology (insurtech) is disrupting the entire insurance industry by providing new cost saving solutions and better customer experiences. It is designed to deliver better processes and greater efficiencies utilizing advanced insurance technologies. A leader in the insurtech sector, InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF) continues to expand an already impressive reach into multiple insurance markets.

The company’s first target is the hospitality sector with intent to dominate what looks to be an incredibly lucrative sector. InsuraGuest Technologies’ latest landmark is the announcement that it has gone live on a vendor partnership with Guesty, the world’s leading end-to-end short-term rental property management software (https://nnw.fm/Zj9xj). InsuraGuest will integrate with the Guesty property management software through its proprietary API, which will enable Guesty’s 60k US property managers to transfer certain liability exposures to the InsuraGuest carrier. By transferring certain liabilities to the InsuraGuest Hospitality Liability coverages, for a small fee of $11.95 per night (which is passed on to the guest), the covered short-term rental properties can lower their claim ratios and risk profiles, which may decrease their general liability and/or homeowners’ premiums.

Alon Eitan, Guesty’s Director of Strategy & Business Development stated, “We are excited to launch our relationship with InsuraGuest. Providing our customers with access to vendors like InsuraGuest helps protect their properties while protecting their guests.”

InsuraGuest Technologies is steamrolling the industry, signing agreements with property management systems and operators, continually expanding the reach of its network. The company’s success has hinged not only the caliber of management but even more so on the quality of its value proposition. With a solid foundation built on the power of its proprietary software platform, InsuraGuest Technologies intends to dominate multiple insuratech markets.

Commenting on the latest partnership, Douglas Anderson, CEO and Chairman of InsuraGuest Technologies stated, “Being able to work with the world’s leading end-to-end short-term rental property management software company means InsuraGuest will have access to market its Hospitality Liability product to property managers who use Guesty to manage their short-term rentals; rentals which are listed on multiple platforms such as Airbnb, HomeAway, Vrbo, TripAdvisor, Agoda, and Booking.com.”

The InsuraGuest expanded platform integration now connects with 90% of all property management systems used by the biggest names in hospitality. The appeal is obvious to operators. Liability usually has limitations and high deductibles. When these incidents are covered by a property’s general liability insurance it could cost a facility more than the actual event and drive-up premiums. InsuraGuest provides a layer of protection that responds to the property directly when guests experience mishaps. Using InsuraGuest may decrease a property’s general liability premiums, thus saving money, time and aggravation for hotel and vacation rental operators. InsuraGuest is transforming the way insurance is delivered – digital insurance reimagined, reinvented, and revolutionized.

For more information, visit the company’s website at www.InsuraGuest.com.

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://nnw.fm/ISGI

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Friendable (FDBL) Builds On Music Fans Engagement Success with Growing Services for Performers

Mobile technology innovator Friendable is pioneering a new venue for marketing musicians and allowing fans more direct access to their favorite performers as part of an emerging trend in digital engagement
Friendable’s Fan Pass app fills a void in the entertainment industry during the closure of in-person concert and convention venues during the COVID pandemic, providing an interactive stage for performers through a monthly app subscription
Friendable has signed more than 700 artists since launching Fan Pass in July
The company recently announced a growing list of “Pro Services” to help its entertainers build their brand online, ranging from logo design to set building
The subscription includes an initial trial-basis offer, followed by a low monthly fee equating to a couple of song downloads

The year 2020 will undoubtedly be remembered in the annals of history for its social and political drama, an idea celebrated in social media memes that feature time travelers recoiling from the thought of visiting that particular point in time.

One innovation to emerge from the year, however, was the advent of direct digital platform engagement between entertainers and their fans during a year when live, in-person performances were all but outlawed as a result of the COVID pandemic. The trend initially manifested as artists started posting brief performances on their social media channels to provide a bit of upbeat distraction during “coronavirus isolation,” ranging from Italian tenor Maurizio Marchini singing opera from his balcony and comedian Steve Martin playing banjo music from a glade of trees (https://nnw.fm/fxvBL) to old-school rockers Blue Oyster Cult presenting a lockdown rendition of “Godzilla” with five band members streaming together from separate locations (https://nnw.fm/ShLA2).

The enthusiasm for such impromptu digital engagement led to its evolution as a way for fans missing out on music concerts and star-studded science fiction conventions to find live, real-time performances from their favorite artists online and even chat one-on-one with them for a modest price. Mobile technology and marketing innovators at Friendable (OTC: FDBL) are establishing themselves as pioneers in delivering this type of fan experience through a proprietary app available on Google Play and the Apple Store.

Since launching in July, Friendable’s Fan Pass platform has added more than 500 artists to its roster. The company recently announced that it is enhancing its ability to provide musicians a customized stage by establishing its “Pro Services” offering for existing artists with plans to soon roll out the service to all new artists during their onboarding and sign-up process (https://nnw.fm/PM8jv).

The Pro Services include logo design, website creation, social media communications, merchandising, set building and lighting, with plans to expand what is offered to artists as the platform grows.

“Our vision for Fan Pass has always been one of supporting both the artists and their fans, and now that we have a variety of artists, live channels, performances and content it’s a natural fit to begin offering additional services that can only enhance each artist brand, as well as boost revenue opportunities on Fan Pass,” Friendable CEO Robert A. Rositano Jr. stated in making the announcement. “In many ways, we are similar to a venture capital firm that nurtures each of its startups with the tools for success; but, in our case, we don’t discriminate based on talent, ideas or stage of career.”

Fan Pass offers initial access to subscribers for free on a trial basis, offering social media access to exclusive VIP experiences, interviews and behind-the-scenes content featuring favored artists, with monthly rates thereafter priced equal to a couple of song downloads.

Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers for free on a trial basis. Thereafter, subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, providing VIP access at a fraction of the cost of traditional face-to-face meetups.

For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com.

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://nnw.fm/FDBL

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Wild Week on Wall Street, What’s Next?

What a wild ride on Wall Street. Individual investors, loosely connected on a social media platform, challenged institutional investors and brought them to their knees using a classic Wall Street tactic to put the squeeze on Wall Street itself.

Featured in a Wall Street Journal article, Keith Gill, an individual trader known as DeepF—ingValue on the Reddit forum WallStreetBets, sparked a Wall Street counterculture and helped turn the investing world upside down. By now, almost everyone has heard of GameStop Corp. (NYSE: GME) and its meteoric rise from obscurity to over 1,700% at its peak. Individual investors on WallStreetbets successfully targeted and chatted up several stocks with extremely high short interest, which triggered short squeezes in many of the targets, forcing short interests to cover. The strategy worked like magic, with buying volume so heavy that hedge funds lost billions and broker dealers like Robinhood temporarily restricting buying in certain stocks to preserve financial solvency. This never-before-seen David vs. Goliath moment in the markets has been punctuated by shrieks of jubilation from thousands of small investors for having “stuck it” to the establishment while cashing in along the way. It wasn’t just GameStop that was targeted. AMC Entertainment Holdings Inc. (NYSE: AMC), the movie theater chain, has surged nearly 840% this year, and BlackBerry Ltd. (NYSE: BB) is up nearly 280%. Wielding the power of technology and decentralization, individual investors have disrupted the long-established Wall Street power dynamic, which begs the question: what’s next?

Maybe the answer in on Mr. Gill’s notepad…

The notepad of DeepF—ingValue (aka Mr. Gill) is pictured in the WSJ article and lists several stock tickers. At the top of the list of stock tickers is ‘TAAT’, the symbol for TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2). This is really intriguing and might even be an indication of where the masses are headed next.

TAAT LIFESTYLE & WELLNESS is an interesting yet little known company guided by savvy and experienced management launching a truly unique product. The company has developed TAAT, a tobacco-free and nicotine-free alternative to traditional cigarettes, and intends to make its mark in the $814 billion global tobacco industry. TAAT’s base material is Beyond Tobacco, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco while emulating the sensory experiences of smoking. Under executive leadership with pedigrees from Big Tobacco, TAAT just launched in the United States in December and is already getting rave reviews. In just its second month of availability at retail in Ohio, TAAT is carried in over 100 tobacco retail stores across the state, and about 60% of retailers who have carried TAAT for three or more weeks have reordered at least once, with several reorders asking for a greater quantity than the first. That’s indicative of a product that could easily catch fire with consumers.

With several hundred million legal-aged smokers worldwide, there’s a tremendous opportunity for a nicotine-free and tobacco-free product such as TAAT to gain market share. TAAT’s proprietary Beyond Tobacco, is a non-tobacco product and has a significant tobacco tax-free price advantage in many states. TAAT’s objective is to build Beyond Tobacco into an iconic and recognizable American consumer brand by persuading current tobacco smokers of legal age to abandon tobacco cigarettes in favor of TAAT.

The company realizes (and maybe Mr. Gill does, too) that if just one pack of Beyond Tobacco a day was sold at 20% of all U.S. tobacco points of sale, it would equate to approximately 2.7 million cartons a year, and TAAT would capture 0.25% of an $800+ billion market. Maybe that’s why TAAT was first on the list of DeepF—ingValue.

For more information, visit the company’s website at www.taatglobal.com.

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.